PTPN2 deficiency along with activation of nuclear Akt predict endocrine resistance in breast cancer

被引:0
作者
Elin Karlsson
Cynthia Veenstra
Jon Gårsjö
Bo Nordenskjöld
Tommy Fornander
Olle Stål
机构
[1] Linköping University,Department of Clinical and Experimental Medicine, Department of Oncology
[2] Karolinska University Hospital and Karolinska Institute,Department of Oncology
来源
Journal of Cancer Research and Clinical Oncology | 2019年 / 145卷
关键词
TCPTP; 18p deletion; PTPN2; Protein tyrosine phosphatase; Breast cancer; Gene copy number; Immunohistochemistry;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:599 / 607
页数:8
相关论文
共 191 条
[1]  
Addou-Klouche L(2010)Loss, mutation and deregulation of L3MBTL4 in breast cancers Mol Cancer 9 213-2149
[2]  
Adelaide J(2010)Subcellular localization of activated AKT in estrogen receptor- and progesterone receptor-expressing breast cancers: potential clinical implications Am J Pathol 176 2139-1633
[3]  
Finetti P(2010)Estrogen receptor-alpha phosphorylation at serine 305, nuclear p21-activated kinase 1 expression, and response to tamoxifen in postmenopausal breast cancer Clin Cancer Res 16 1624-406
[4]  
Cervera N(2013)Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit Breast Cancer Res Treat 137 397-246
[5]  
Ferrari A(2014)Characterization of PTPN2 and its use as a biomarker Methods 65 239-9824
[6]  
Bekhouche I(2001)Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance J Biol Chem 276 9817-3869
[7]  
Sircoulomb F(2002)Genomic loss of 18p predicts an adverse clinical outcome in patients with high-risk breast cancer Clin Cancer Res 8 3863-2108
[8]  
Sotiriou C(2003)Regulation of insulin receptor signaling by the protein tyrosine phosphatase TCPTP Mol Cell Biol 23 2096-829
[9]  
Viens P(2005)Coordinated regulation of insulin signaling by the protein tyrosine phosphatases PTP1B and TCPTP Mol Cell Biol 25 819-1246
[10]  
Moulessehoul S(2014)Protein tyrosine phosphatases as potential therapeutic targets Acta Pharmacol Sin 35 1227-3616